Keyphrases
Israel
100%
Enterobacteriaceae
52%
Klebsiella Pneumoniae (K. pneumoniae)
44%
Extended-spectrum-lactamase
43%
Risk Factors
34%
Carbapenemase-producing Enterobacterales
34%
Klebsiella Pneumoniae Carbapenemase
30%
Israeli
29%
Medical Center
29%
Tel Aviv
26%
Clostridioides Difficile
25%
Colistin
24%
Antimicrobial Resistance
23%
Escherichia Coli
22%
Carbapenem-resistant Enterobacteriaceae
21%
Epidemiology
20%
Neonatal Intensive Care Unit
20%
COVID-19
18%
Epidemiological Characteristics
18%
Plasmid
18%
Bloodstream Infection
17%
Rehabilitation Centers
16%
Clostridium Difficile Infection
16%
OXA-48
15%
Meropenem
15%
Carbapenems
14%
Tertiary Care Hospital
14%
Multidrug-resistant Gram-negative Bacteria
14%
Molecular Features
14%
Clinical Characteristics
14%
Enterobacterales
14%
C-reactive Protein
13%
Neonate
13%
Antibiotic Resistance
13%
Core Genome multilocus Sequence Typing (cgMLST)
12%
KPC-producing Klebsiella Pneumoniae
12%
Carbapenem-resistant Acinetobacter Baumannii
12%
Confidence Interval
12%
Acinetobacter Baumannii (A. baumannii)
12%
Antimicrobial
12%
Bacteremia
12%
Clinical Features
12%
ESBL-producing Enterobacteriaceae
11%
KPC-2
11%
Multidrug-resistant
11%
National Survey
11%
Acute Hospital
11%
Randomized Controlled Trial
11%
Europe
11%
Carbapenemase-producing
11%
Medicine and Dentistry
Infection
73%
Bloodstream Infection
38%
Carbapenem
33%
Penicillinase
29%
Carbapenemase
28%
Beta-Lactamase
28%
Klebsiella pneumoniae
28%
Enterobacteriaceae
24%
Extended Spectrum Beta Lactamase
23%
Clostridium Difficile Infection
21%
COVID-19
20%
Colistimethate
18%
Carbapenemase Producing Enterobacteriaceae
16%
Gram-Negative Bacteria
16%
Peptoclostridium difficile
15%
Antibiotic Resistance
15%
C Reactive Protein
13%
Cohort Effect
12%
Neonatal Intensive Care Unit
12%
Escherichia coli
11%
Antibiotics
11%
Carbapenem-Resistant Enterobacteriaceae
11%
Neonate
11%
Antibiotic Therapy
10%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
10%
Randomized Controlled Trial
10%
Rehabilitation Center
10%
Health Care
10%
Tertiary Care
10%
Prevalence
9%
Odds Ratio
9%
Pathogen
9%
Antiinfective Agent
9%
Meropenem
9%
Acinetobacter Baumannii
8%
Gastroenteritis
8%
Antibiogram
7%
Long-Term Care
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Neonatal Infant
7%
Streptococcus pneumonia
7%
Pneumococcal Pneumonia
7%
Gram Negative Sepsis
7%
Case-Control Study
7%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
7%
Retrospective Study
7%
Intensive Care Unit
7%
Oncology
6%
Emergency Medicine
6%
Human Immunodeficiency Virus
6%